Bluejay Diagnostics, Inc. (BJDX) — SEC Filings

Latest SEC filings for Bluejay Diagnostics, Inc. (BJDX), explained in plain English.

Sentiment Overview: 1 bullish, 4 bearish, 40 neutral

Recent Filings (45)

• Bluejay Diagnostics Files 8-K with Press Release — 8-K · 2026-04-07T09:09:05-04:00 [neutral] Risk: low
  Bluejay Diagnostics, Inc. filed an 8-K on April 7, 2026, to report a press release dated the same day. The filing includes financial statements and exhibits, bu
• 8-K Filing — 8-K · 2025-12-30T00:00:00.000Z [neutral]
• Bluejay Diagnostics Files 8-K Report — 8-K · 2025-11-10T00:00:00.000Z [neutral] Risk: low
  On November 10, 2025, Bluejay Diagnostics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibit
• Bluejay Diagnostics Narrows Loss, Seeks $20M for Sepsis Test Development — 10-Q · 2025-11-07T00:00:00.000Z [bearish] Risk: high
  Bluejay Diagnostics, Inc. (BJDX) reported a net loss of $1,597,632 for the three months ended September 30, 2025, a decrease from the $1,481,959 net loss in the
• Bluejay Diagnostics Files 8-K: Material Agreement & Equity Sales — 8-K · 2025-10-14T00:00:00.000Z [neutral] Risk: medium
  On October 9, 2025, Bluejay Diagnostics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
• Bluejay Diagnostics Files 8-K Report — 8-K · 2025-10-09T00:00:00.000Z [neutral] Risk: low
  On October 3, 2025, Bluejay Diagnostics, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures
• Bluejay Diagnostics Files 8-K Report — 8-K · 2025-08-15T00:00:00.000Z [neutral] Risk: low
  On August 15, 2025, Bluejay Diagnostics, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details re
• Bluejay Diagnostics Files 8-K Report — 8-K · 2025-08-11T00:00:00.000Z [neutral] Risk: low
  On August 7, 2025, Bluejay Diagnostics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits.
• Bluejay Diagnostics Posts $2.5M Loss, R&D Down 20% — 10-Q · 2025-08-07T00:00:00.000Z [bearish] Risk: high
  Bluejay Diagnostics, Inc. reported no revenue for the quarter ended June 30, 2025, consistent with its pre-commercial stage. The company incurred a net loss of
• Bluejay Diagnostics Enters Material Definitive Agreement — 8-K · 2025-07-28T00:00:00.000Z [neutral] Risk: medium
  On July 23, 2025, Bluejay Diagnostics, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive off
• Bluejay Diagnostics Files 8-K on Shareholder Votes — 8-K · 2025-06-20T00:00:00.000Z [neutral] Risk: low
  Bluejay Diagnostics, Inc. filed an 8-K on June 20, 2025, reporting on matters submitted to a vote of security holders as of June 18, 2025. The filing details th
• Bluejay Diagnostics Files 8-K with Financials — 8-K · 2025-06-04T00:00:00.000Z [neutral] Risk: low
  On June 3, 2025, Bluejay Diagnostics, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits, with no other
• Bluejay Diagnostics Files 8-K: Officer & Director Changes — 8-K · 2025-05-28T00:00:00.000Z [neutral] Risk: medium
  Bluejay Diagnostics, Inc. filed an 8-K on May 28, 2025, reporting changes in its board of directors and certain officers, along with updates on compensatory arr
• Bluejay Diagnostics Files Definitive Proxy Statement — DEF 14A · 2025-05-16T00:00:00.000Z [neutral] Risk: low
  Bluejay Diagnostics, Inc. filed its definitive proxy statement on May 16, 2025, for its annual meeting of stockholders scheduled for June 18, 2025. The filing o
• Bluejay Diagnostics Files Q1 2025 10-Q — 10-Q · 2025-05-13T00:00:00.000Z [neutral] Risk: low
  Bluejay Diagnostics, Inc. filed its 10-Q for the quarterly period ended March 31, 2025. The company, incorporated in Delaware with its principal executive offic
• Bluejay Diagnostics Files 2024 Annual Report Amendment — 10-K/A · 2025-04-29T00:00:00.000Z [neutral] Risk: low
  Bluejay Diagnostics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated April 29, 2025, provid
• Bluejay Diagnostics Files 8-K — 8-K · 2025-04-09T00:00:00.000Z [neutral] Risk: medium
  On April 7, 2025, Bluejay Diagnostics, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities a
• Bluejay Diagnostics Files 2024 Annual Report — 10-K · 2025-03-31T00:00:00.000Z [neutral] Risk: medium
  Bluejay Diagnostics, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2024. The company, incorporated in Delaware with its princ
• Bluejay Diagnostics Updates Corporate Address and Phone — 8-K · 2024-12-04T00:00:00.000Z [neutral] Risk: low
  On December 3, 2024, Bluejay Diagnostics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 360 Massachuse
• Bluejay Diagnostics Files 8-K with Key Corporate Updates — 8-K · 2024-11-18T00:00:00.000Z [neutral] Risk: medium
  On November 15, 2024, Bluejay Diagnostics, Inc. filed an 8-K report detailing several key events. The company announced a material modification to the rights of
• SC 13G Filing — SC 13G · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• Bluejay Diagnostics Files Q3 2024 10-Q Report — 10-Q · 2024-11-07T00:00:00.000Z [neutral] Risk: medium
  Bluejay Diagnostics, Inc. filed its 10-Q for the quarterly period ended September 30, 2024. The company, incorporated in Delaware, reported its financial status
• Bluejay Diagnostics Files 8-K on Shareholder Vote Matters — 8-K · 2024-10-24T00:00:00.000Z [neutral] Risk: low
  Bluejay Diagnostics, Inc. filed an 8-K on October 24, 2024, reporting on matters submitted to a vote of its security holders as of October 23, 2024. The filing
• Bluejay Diagnostics Files 8-K for Bylaws and Exhibits — 8-K · 2024-10-16T00:00:00.000Z [neutral] Risk: low
  On October 16, 2024, Bluejay Diagnostics, Inc. filed an 8-K report. The filing primarily concerns amendments to its articles of incorporation or bylaws and the
• Bluejay Diagnostics Files Definitive Proxy Statement — DEF 14A · 2024-09-10T00:00:00.000Z [neutral] Risk: low
  Bluejay Diagnostics, Inc. filed a definitive proxy statement (DEF 14A) on September 10, 2024, for its annual meeting of stockholders. The filing indicates that
• Bluejay Diagnostics Faces Delisting Concerns — 8-K · 2024-08-28T00:00:00.000Z [bearish] Risk: high
  Bluejay Diagnostics, Inc. filed an 8-K on August 28, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The company's principa
• Bluejay Diagnostics Files 8-K on Security Holder Vote — 8-K · 2024-08-21T00:00:00.000Z [neutral] Risk: low
  On August 21, 2024, Bluejay Diagnostics, Inc. filed an 8-K report to announce the submission of matters to a vote of its security holders. The filing does not c
• Bluejay Diagnostics Files Q2 2024 10-Q Report — 10-Q · 2024-08-14T00:00:00.000Z [neutral] Risk: medium
  Bluejay Diagnostics, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2024. The company, incorporated in Delaware, is based in Acton,
• Bluejay Diagnostics Files Definitive Proxy Statement — DEF 14A · 2024-07-16T00:00:00.000Z [neutral] Risk: low
  Bluejay Diagnostics, Inc. filed a definitive proxy statement (DEF 14A) on July 16, 2024, for its annual meeting of stockholders scheduled for August 21, 2024. T
• SC 13G Filing — SC 13G · 2024-07-03T00:00:00.000Z [neutral]
• Bluejay Diagnostics Files 8-K with Material Agreement — 8-K · 2024-06-28T00:00:00.000Z [neutral] Risk: medium
  On June 27, 2024, Bluejay Diagnostics, Inc. entered into a Material Definitive Agreement. The company also reported other events and filed financial statements
• Bluejay Diagnostics Files S-1/A Amendment — S-1/A · 2024-06-24T00:00:00.000Z [neutral] Risk: medium
  Bluejay Diagnostics, Inc. filed an S-1/A amendment on June 24, 2024, for its initial public offering. The company, incorporated in Delaware, is seeking to regis
• Bluejay Diagnostics Files 8-K on Security Holder Rights — 8-K · 2024-06-20T00:00:00.000Z [neutral] Risk: medium
  Bluejay Diagnostics, Inc. filed an 8-K on June 20, 2024, reporting material modifications to security holder rights and other events as of June 17, 2024. The fi
• Bluejay Diagnostics Files S-1 for Public Offering — S-1 · 2024-06-17T00:00:00.000Z [neutral] Risk: medium
  Bluejay Diagnostics, Inc. filed an S-1 registration statement on June 17, 2024, to register securities under the Securities Act of 1933. The company, incorporat
• Bluejay Diagnostics Enters Loan Agreement, Sells Equity — 8-K · 2024-05-31T00:00:00.000Z [neutral] Risk: medium
  On May 31, 2024, Bluejay Diagnostics, Inc. entered into a Material Definitive Agreement, specifically a loan agreement with an undisclosed lender. This agreemen
• Bluejay Diagnostics Raises $1M, CFO Departs — 8-K · 2024-05-16T00:00:00.000Z [neutral] Risk: medium
  On May 14, 2024, Bluejay Diagnostics, Inc. filed an 8-K report detailing several key events. The company announced the closing of a private placement of convert
• Bluejay Diagnostics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-15T00:00:00.000Z [neutral] Risk: low
  Bluejay Diagnostics, Inc. (BJDX) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Bluejay Diagnostics, Inc. filed a Form 10-Q for the quarterly per
• Bluejay Diagnostics, Inc. Announces Annual Meeting of Stockholders on May 14, 2024 — DEF 14A · 2024-04-15T00:00:00.000Z [neutral] Risk: low
  Bluejay Diagnostics, Inc. (BJDX) filed a Proxy Statement (DEF 14A) with the SEC on April 15, 2024. Bluejay Diagnostics, Inc. will hold its Annual Meeting of Sto
• Bluejay Diagnostics Announces Board and Compensation Changes — 8-K · 2024-04-02T00:00:00.000Z [neutral] Risk: medium
  Bluejay Diagnostics, Inc. announced on March 29, 2024, a change in its board of directors and executive compensation arrangements. The filing details the depart
• Bluejay Diagnostics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · 2024-03-28T00:00:00.000Z [neutral] Risk: low
  Bluejay Diagnostics, Inc. (BJDX) filed a Annual Report (10-K) with the SEC on March 28, 2024. Bluejay Diagnostics, Inc. filed its annual report on Form 10-K for
• Bluejay Diagnostics Faces Delisting Concerns — 8-K · 2024-03-04T00:00:00.000Z [bearish] Risk: high
  Bluejay Diagnostics, Inc. filed an 8-K on March 4, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the ea
• SC 13G Filing — SC 13G · 2024-02-14T00:00:00.000Z [neutral]
• Sabby Volatility Fund Discloses 177,513 Share Stake in Bluejay Diagnostics — SC 13G · 2024-01-03T00:00:00.000Z [bullish]
  Sabby Volatility Warrant Master Fund, Ltd., a Cayman Islands-based entity, reported on January 3, 2024, that it beneficially owns 177,513 shares of Bluejay Diag
• Bluejay Diagnostics Files 8-K on Material Agreement, Other Events — 8-K · 2024-01-02T00:00:00.000Z [neutral]
  Bluejay Diagnostics, Inc. filed an 8-K on January 2, 2024, reporting an event that occurred on December 27, 2023. This filing indicates the company entered into